Mutations in the Notch signaling pathway are associated with increased tumor-specific CD8+ T cell count, decreased inhibitory regulatory T cell count, enhanced antitumor immunity, early disease occurrence, and lower metastasis rates in patients with CRC [17]. This evidence concerns the gene CD8A and neoplasm.